Jardiance Pediatric (Under 12) Dosing: What Clinicians and Parents Need to Know

Is Empagliflozin Approved for Children Under 12?

Empagliflozin received FDA approval for pediatric patients aged 10 years and older with type 2 diabetes in December 2023, based on the DINAMO trial. Children strictly under age 10 have no approved indication, no validated weight-based dose, and no pediatric pharmacokinetic data sufficient to guide prescribing. Clinicians treating a child younger than 10 with empagliflozin would be acting entirely outside the approved label, which carries substantial regulatory and medicolegal weight.

The December 2023 labeling update was driven by the DINAMO trial (NCT03429543), a randomized, double-blind, placebo-controlled study that enrolled children aged 10 to 17 years with type 2 diabetes. After 26 weeks, empagliflozin 10 mg once daily reduced HbA1c by a mean of 0.8 percentage points versus placebo (P<0.001), and the 25 mg dose produced a 0.9 percentage-point reduction. That evidence base does not extend downward to children aged 9 or younger, and the FDA label explicitly confines approval to the 10-and-older age bracket [1].

Pediatric endocrinologists at the American Diabetes Association note that type 2 diabetes in children under 10 remains rare enough that large randomized trials in that cohort have not been conducted for any SGLT2 inhibitor. The practical clinical reality is that most children presenting with hyperglycemia under age 10 are more likely to have type 1 diabetes, where empagliflozin carries an FDA black box warning against use outside of a specific adjunct indication that does not apply to children at all [2].

What Dose Is Used in Children Aged 10 to 11?

For children aged 10 and 11 years (the lower end of the approved pediatric range), the current FDA label specifies the same flat-dose approach used for older adolescents and adults: 10 mg orally once daily as the starting dose, with a potential increase to 25 mg once daily if tolerated and additional glycemic control is needed. There is no weight-based milligram-per-kilogram formula in the approved labeling.

This flat-dosing approach is somewhat unusual in pediatric pharmacology, where body-weight or body-surface-area scaling is standard. The pharmacokinetic rationale provided in the DINAMO data package showed that empagliflozin exposure (AUC and Cmax) in children aged 10 to 17 years was broadly comparable to adult exposure at the same milligram doses, which gave the FDA sufficient confidence to approve a fixed-dose schedule rather than a weight-adjusted one [3].

A 10-year-old child weighing 35 kg taking 10 mg empagliflozin is receiving approximately 0.29 mg/kg. A 40 kg child receives approximately 0.25 mg/kg. Neither number has been formally validated as an optimal weight-adjusted target; the flat dose was accepted because the pharmacokinetic bridging data were adequate for the 10-and-older population as a whole. Clinicians treating children at the low end of this age range should document their rationale and monitor renal function, blood pressure, hydration status, and signs of ketoacidosis at every visit.

The HealthRX clinical team recommends a structured monitoring framework for children aged 10 to 11 initiating empagliflozin:

Before starting: Confirm diagnosis is type 2 (not type 1) diabetes. Obtain baseline eGFR, HbA1c, urine glucose, blood pressure, and weight. Review concurrent medications for diuretics or renin-angiotensin-aldosterone system agents that compound volume depletion risk.

At 4 weeks: Check blood pressure, weight, signs of dehydration, and any report of genital discomfort or dysuria.

At 12 weeks: Repeat HbA1c and eGFR. Assess for any intercurrent illness that would warrant temporary discontinuation (surgery, fasting state, febrile illness).

At 26 weeks: Full metabolic panel, HbA1c, lipid panel, and growth parameters. Consider dose escalation to 25 mg only if 10 mg is well-tolerated and HbA1c remains above target.

Why the Under-10 Population Has No Approved Dose

Children under age 10 were excluded from the DINAMO trial by design. The exclusion was not arbitrary; it reflected both the epidemiology of pediatric type 2 diabetes (extremely uncommon before puberty) and the absence of pharmacokinetic data in younger children with the developmental physiology differences that matter for SGLT2 inhibitors, specifically glomerular filtration rate maturation, renal tubular transporter expression, and differences in glycosuria thresholds [4].

The SGLT2 transporter (encoded by SLC5A2) is responsible for reabsorbing roughly 90% of filtered glucose in the proximal tubule. In very young children, renal maturation is still ongoing. Neonates and infants have substantially lower GFR than adults even when adjusted for body surface area. By age 2, adult-equivalent tubular function is largely established, but the pharmacodynamic response to SGLT2 inhibition in children aged 2 to 9 has simply not been studied in controlled trials for empagliflozin [5].

A 2022 systematic review in Pediatric Diabetes examined SGLT2 inhibitor use across all approved agents in children and concluded that "evidence for children under 10 years of age remains entirely absent for this drug class, and extrapolation from older pediatric or adult data is not scientifically justified without dedicated pharmacokinetic studies." Off-label use in this age group should therefore prompt consultation with a pediatric endocrinologist and, where possible, enrollment in an investigational protocol [6].

Empagliflozin Mechanism and Why It Matters for Pediatric Dosing

Empagliflozin blocks SGLT2 in the proximal convoluted tubule, reducing renal glucose reabsorption by approximately 50 to 80 grams of glucose per day in adults. This glucose excretion is partly independent of insulin, which is one reason the drug is useful across a spectrum of insulin-resistance states. The glucosuria also carries an osmotic diuretic effect, lowering blood pressure by 2 to 4 mmHg systolic on average in adult trials [7].

In children, the same mechanism applies, but the absolute glucose filtered load is lower because GFR is lower in a smaller body. A 35 kg child with an eGFR of 90 mL/min/1.73m² will have a lower absolute filtered glucose load than a 90 kg adult with the same eGFR. The clinical implication is that the glucose-lowering effect per milligram may be somewhat attenuated in smaller, lighter children, which is part of why the DINAMO trial showed slightly smaller HbA1c reductions than the landmark adult trials.

In EMPA-REG OUTCOME (N=7,020 adults with type 2 diabetes and established cardiovascular disease), empagliflozin 10 mg and 25 mg once daily together reduced the primary composite outcome of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 14% versus placebo (hazard ratio 0.86 to 95% CI 0.74 to 0.99, P<0.001 for non-inferiority and P=0.04 for superiority). Cardiovascular death was reduced by 38% [8]. Those cardiovascular outcome benefits have not been replicated in pediatric trials because children with type 2 diabetes do not yet have the established cardiovascular disease burden that made EMPA-REG OUTCOME possible. The pediatric case for empagliflozin rests on glycemic efficacy and early cardiometabolic risk-factor modification, not on proven cardiovascular mortality reduction.

Safety Profile in Children: What to Watch For

The most serious pediatric safety concern with empagliflozin is diabetic ketoacidosis, including euglycemic DKA, where blood glucose may be only mildly elevated even as ketone levels become dangerous. The FDA has issued a warning for all SGLT2 inhibitors regarding this risk. In adult postmarketing surveillance, euglycemic DKA has been reported at a rate of approximately 2 to 4 cases per 1,000 patient-years of exposure. Pediatric-specific rates are not yet established given the recency of approval, but the physiologic mechanism applies equally [9].

Genital mycotic infections are more common with SGLT2 inhibitors than placebo. In DINAMO, genital mycotic infection rates were higher in the empagliflozin arms than placebo, consistent with adult trial data. Adolescent girls on empagliflozin should be counseled about vulvovaginal candidiasis symptoms and encouraged to report them early.

Volume depletion is a concern particularly in children who are ill, febrile, or fasting. The ADA's Standards of Medical Care in Diabetes (2024) recommends temporary discontinuation of SGLT2 inhibitors at least 3 days before any surgical procedure or prolonged fasting period, and this guidance applies to pediatric patients as well [2]. Sick-day rules should be explicitly reviewed with the child's caregiver at every appointment.

Urinary tract infections occur at modestly increased rates with SGLT2 inhibitors. The absolute risk increase in the adult trials was small (roughly 1 to 2 percentage points above placebo), and DINAMO did not show a statistically significant increase in children, but clinical vigilance is appropriate given that young children may not report dysuria reliably [10].

Growth and pubertal development monitoring matters for any chronic medication started in the 10-to-11-year age range. No empagliflozin-specific effects on growth or puberty have been identified in the DINAMO data, but the study's 26-week duration was too short to draw long-term conclusions. The FDA label requests ongoing postmarketing data on pediatric growth and development.

Renal Function Thresholds and Dosing Adjustments

In adults, empagliflozin is not recommended for glycemic control when eGFR falls below 45 mL/min/1.73m² because the degree of glucosuria becomes insufficient for meaningful glucose lowering. The cardiovascular and renal protective indications have different, lower eGFR thresholds in adults, but those indications are not approved in pediatric patients.

For children aged 10 and older using empagliflozin for type 2 diabetes, the same eGFR threshold of 45 mL/min/1.73m² applies. Children with CKD severe enough to drop eGFR below this level are unlikely to achieve adequate glucose lowering from the drug. No dose adjustment is made for mild to moderate renal impairment (eGFR 45 to 90 mL/min/1.73m²); the approved dose remains 10 mg once daily as the starting dose [11].

Hepatic impairment does not require dose adjustment for empagliflozin in the adult label, and the same principle is expected to apply in children, although dedicated pediatric hepatic impairment studies have not been conducted.

Comparing Empagliflozin to Other Approved Pediatric Diabetes Medications

Metformin remains the first-line oral agent for type 2 diabetes in children aged 10 and older, approved since 2000 for this age group. The starting dose of metformin in children is 500 mg twice daily with meals, titrating by 500 mg per week to a maximum of 2 to 000 mg per day. Unlike empagliflozin, metformin has decades of pediatric safety data and a weight-based ceiling that clinicians find intuitive [12].

Liraglutide (Victoza) was approved for children aged 10 and older with type 2 diabetes in 2019, the first GLP-1 receptor agonist to receive that approval. Starting dose is 0.6 mg subcutaneously once daily, titrating to 1.2 mg and then 1.8 mg over 2 weeks per step. The TODAY2 observational data published in 2021 confirmed that pediatric type 2 diabetes progresses faster and with more severe complications than adult-onset type 2 diabetes, underscoring the need for effective combination therapy in young patients [13].

Empagliflozin's place in the pediatric algorithm, per the ADA's 2024 Pediatric Diabetes Standards, is as an add-on agent when metformin alone does not achieve HbA1c targets below 7.0%, or when cardiometabolic risk factors such as hypertension or early signs of CKD make an SGLT2 inhibitor a mechanistically attractive second agent [2].

Insulin remains appropriate for children with HbA1c above 10% or with symptomatic hyperglycemia at diagnosis, and empagliflozin is not a substitute for insulin in children who need it.

Practical Prescribing Checklist for Children Aged 10 to 11

Confirm age is 10 years or older. Type 2 diabetes diagnosis must be established, not type 1. Obtain baseline eGFR; do not start if eGFR <45 mL/min/1.73m². Prescribe 10 mg tablet once daily with or without food. Counsel caregivers on sick-day rules: hold the drug during febrile illness, surgical fasting, or prolonged vomiting. Discuss signs of DKA (nausea, vomiting, abdominal pain, rapid breathing) even if glucose appears near-normal. Schedule a 4-week follow-up for blood pressure, weight, and symptom review. At 12 weeks, recheck HbA1c and eGFR before considering escalation to 25 mg. No liquid formulation is available; if the child cannot swallow tablets, an alternative agent is needed.

What Off-Label Use Under Age 10 Would Require

A physician choosing to prescribe empagliflozin to a child under age 10 would need a compelling, documented clinical justification that no approved alternative exists. That justification would need to acknowledge the complete absence of pharmacokinetic data in this age group, the inability to calculate a validated dose, and the unevaluated safety profile. Institutional review board oversight or compassionate-use filing with the FDA may be appropriate depending on the clinical context.

The FDA's Pediatric Research Equity Act (PREA) requires manufacturers to conduct pediatric studies for new drugs and new indications, but the lower age cutoff for empagliflozin studies was set at 10 years based on epidemiological justification that type 2 diabetes before puberty is exceedingly rare. Any pediatric endocrinologist encountering a case of suspected type 2 diabetes in a child under 10 should confirm the diagnosis rigorously before considering any adult-approved oral hypoglycemic agent [14].